In inpatients with COVID-19 who need supplemental oxygen, lenzilumab increased ventilation-free survival.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35377717.
- Also identified by DOI 10.7326/J22-0019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Temesgen Z, Burger CD, Baker J, et al. <b>Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.</b> Lancet Respir Med. 2022;10:237-46. 34863332.
Medical subject headings
- COVID-19